ArticleBlood cancer journal2026

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Shin Yeu Ong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.